Publication | Open Access

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Progression-free SurvivalBreast OncologyOncologyHer2-targeted AgentsSurrogate End PointPathologyBreast CancerCancer TreatmentMedicineRadiation OncologyMolecular OncologyEndocrine-related Cancer